Allianz Asset Management Gmb H Editas Medicine, Inc. Transaction History

Allianz Asset Management Gmb H

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$39.71 - $90.58 $303,980 - $693,389	-7,655 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $207,220 - $645,699	7,655 New	7,655 $536,000
Q2 2019 Aug 08, 2019	SELL	$20.48 - $27.76 $1.34 Million - $1.81 Million	-65,360 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$19.43 - $26.41 $322,829 - $438,802	-16,615 Reduced 20.27%	65,360 $1.6 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $5,966 - $10,427	-328 Reduced 0.4%	81,975 $1.82 Million
Q3 2018 Nov 13, 2018	SELL	$27.65 - $38.39 $2.06 Million - $2.86 Million	-74,590 Reduced 47.54%	82,303 $2.62 Million
Q2 2018 Aug 13, 2018	BUY	$31.4 - $41.01 $496,057 - $647,875	15,798 Added 11.2%	156,893 $5.62 Million
Q1 2018 May 14, 2018	BUY	$29.84 - $44.08 $8,206 - $12,122	275 Added 0.2%	141,095 $4.68 Million
Q4 2017 Feb 13, 2018	BUY	$21.89 - $31.34 $107,589 - $154,036	4,915 Added 3.62%	140,820 $4.33 Million
Q3 2017 Nov 13, 2017	BUY	$15.81 - $24.01 $2.15 Million - $3.26 Million	135,905	135,905 $3.26 Million

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.